^
CANCER:

Ovarian Serous Adenocarcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
BRAF V600E
Ovarian Serous Adenocarcinoma
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600E
Ovarian Serous Adenocarcinoma
encorafenib + binimetinib
Sensitive
:
C1
BRCA2 mutation
Ovarian Serous Adenocarcinoma
olaparib
Sensitive
:
C1
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib
Sensitive
:
C1
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib + ACR-368
Sensitive
:
C2
KRAS G12V
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive
:
C2
KRAS G12D
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive
:
C3
KRAS G12A
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive
:
C3
Choline elevation
Ovarian Serous Adenocarcinoma
pembrolizumab
Sensitive
:
C3
SERPINE1 expression
Ovarian Serous Adenocarcinoma
trametinib
Sensitive
:
C3
BRCA2 deletion
Ovarian Serous Adenocarcinoma
bevacizumab
Sensitive
:
C3
BRCA1 deletion
Ovarian Serous Adenocarcinoma
bevacizumab
Sensitive
:
C3
BRCA1 mutation
Ovarian Serous Adenocarcinoma
AZD1775
Sensitive
:
C4
GOPC-ROS1 fusion
Ovarian Serous Adenocarcinoma
crizotinib
Sensitive
:
C4
ER Y537N
Ovarian Serous Adenocarcinoma
fulvestrant
Sensitive
:
C4
TMB-H + MSH6 F1088fs
Ovarian Serous Adenocarcinoma
pembrolizumab
Sensitive
:
C4
BRCA2 mutation
Ovarian Serous Adenocarcinoma
ACR-368 + LY3023414
Sensitive
:
D
BRAF L485-P490 deletion
Ovarian Serous Adenocarcinoma
LY3009120
Sensitive
:
D
PRMT1 underexpression
Ovarian Serous Adenocarcinoma
carboplatin
Sensitive
:
D
PRMT1 underexpression
Ovarian Serous Adenocarcinoma
cisplatin
Sensitive
:
D